The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

Transdermal oestradiol patches are non-inferior to luteinising hormone-releasing hormone agonists for metastasis free survival in locally advanced prostate cancer, a study shows.

TTUHSC researcher Srinivas Nandana, Ph.D., (left) and co-investigator Manisha Tripathi, Ph.D., received a grant from the U.S. Department of Defense to investigate the role of TBX2 in establishing the ...

New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in ...

PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer ...

Cribriform-positive prostate cancer outcomes needs to be further risk stratified to identify patients at high risk for metastasis.

*Classification performance AUC and balanced accuracy (mean and std, %) using case-level bags on final tiles with a fixed feature setting and dino cls keep=4. Best result per column in bold. This is ...

Sept. 18, 2025 -- About 1 in 8 men will face a prostate cancer diagnosis. Early-stage prostate cancer often has no symptoms—so how should men approach screening and advocacy? What disparities do Black ...

Prostate cancer is one of the most common malignancies affecting men globally, usually developing within the prostate gland. While in its early stages, the disease is often confined to the gland ...

Grant Learmont — 40-year-old from Dumfries, Scotland — was always an active dad of two. He played football, ran half ...